Angelman syndrome is rare (about 1 in 15,000), but it’s one of the most actionable neurogenetic conditions. The Foundation for Angelman Syndrome Therapeutics (FAST), the largest non-governmental funder of Angelman syndrome research, is turning that potential into tools that labs can use now.
With Yale University and EBiSC, FAST has funded and built a curated panel of Angelman syndrome iPSC lines that reflect the real genetics seen in clinic: full range of AS genotypes, deletion, point mutations, UPD, ICD, and relevant controls. These lines are available for pre-order via EBiSC so teams can move faster on target validation, screening, and mechanism studies.
Explore and request lines: https://ebisc.org/search?q=Yui&disease-super-classes=[]
Interested in working with FAST? Explore their research programs and funding opportunities at www.cureangelman.org/research.
#CureAngelman #AngelmanSyndrome #RareDisease #research #EBiSC